Dive Brief:

简报：

AbbVie is joining the industry’s rush to develop new obesity medicines,

AbbVie 也加入了该行业开发新肥胖症药物的热潮，

announcing Monday

周一宣布

a deal with Denmark-based Gubra to license a drug that could compete with experimental therapies being developed by Novo Nordisk, Eli Lilly and Zealand Pharma.

与丹麦Gubra达成协议，授权一种可能与诺和诺德、礼来和Zealand Pharma正在开发的实验性疗法竞争的药物。

Per deal terms, AbbVie will pay Gubra $350 million up front and offer up to $1.9 billion in additional payments tied to the achievement of development and sales milestones. AbbVie will assume responsibility for development and commercialization.

根据协议条款，艾伯维将向Gubra支付3.5亿美元的预付款，并提供高达19亿美元的额外付款，与开发和销售里程碑的达成相关。艾伯维将负责开发和商业化工作。

Gubra is developing a type of drug called an amylin analog that regulates appetite and blood sugar levels. If successful, these drugs could be used as alternatives to or in combination with marketed drugs like Novo’s Wegovy and Lilly’s Zepbound to increase weight loss or reduce side effects.

Gubra公司正在开发一种叫做胰淀素类似物的药物，这种药物可以调节食欲和血糖水平。如果成功，这些药物可以作为诺和诺德的Wegovy和礼来的Zepbound等已上市药物的替代品或联合使用，以增加减重效果或减少副作用。

Dive Insight:

潜水洞察：

Lilly and Novo have a significant lead on the obesity field, as they market the only two blockbuster drugs proven in testing to result in double-digit percentage weight loss. But those GLP-1 drugs have drawbacks, including side effects like nausea and vomiting in many people who take the once-weekly shots.

礼来和诺和诺德在肥胖症领域有显著的领先优势，因为他们销售的两种重磅药物在测试中被证明可以使体重下降达到两位数的百分比。但这些GLP-1类药物也有缺点，包括许多服用每周一次注射剂的人会出现恶心和呕吐等副作用。

They also have .

他们也有。

high discontinuation rates

高停用率

due to those side effects as well as their costs.

由于这些副作用以及它们的成本。

Those shortcomings, along with the draw of a market forecast to exceed $100 billion annually by the 2030s, have energized obesity drug research and dealmaking. Even companies like AbbVie and Amgen that don’t have a long track record in metabolic drugs are getting involved.

这些缺点，再加上到 2030 年代每年市场规模预计将超过 1000 亿美元的吸引力，激发了肥胖症药物的研究和交易活动。甚至连艾伯维和安进这样在代谢药物方面没有长期记录的公司也参与其中。

AbbVie found an attractive deal with Gubra, which is developing an agent it calls GUB014295 or GUBamy. The experimental drug has completed a Phase 1 dosing trial in men considered lean or overweight by body-mass index. Trial volunteers who received the highest dose lost an average of 3% of their body weight over six weeks..

AbbVie 与 Gubra 达成了一项颇具吸引力的交易，后者正在开发一种名为 GUB014295 或 GUBamy 的药物。这种实验性药物已经在根据身体质量指数判定为瘦或超重的男性中完成了第一阶段的剂量试验。接受最高剂量的试验志愿者在六周内平均减掉了 3% 的体重。

An additional dosing trial is underway, with results from various parts of that study due to be available throughout 2025.

一项额外的剂量试验正在进行中，该研究不同部分的结果预计将在2025年全年陆续公布。

At this stage of development, Gubra’s candidate is around a year and a half behind Zealand, which has an amylin-targeting drug in a Phase 2 trial due to read out in 2026, Cantor Fitzgerald analyst Prakhar Agrawal wrote in a note to clients.

在这一发展阶段，古布拉的候选药物比 Zealand 落后大约一年半，Zealand 有一种针对胰淀素的药物正处于二期临床试验阶段，预计将在 2026 年公布结果，康托·菲茨杰拉德公司分析师普拉哈尔·阿格拉瓦尔在给客户的一份报告中写道。

Novo, meanwhile, already has Phase 3 data on its amylin drug cagrilintide, which was assessed in a trial alone and as part of a

与此同时，诺和已经获得了其艾米林药物cagrilintide的三期数据，该药物在试验中单独使用以及作为组成部分进行了评估。

combination with Wegovy

与Wegovy联合使用

called CagriSema. Lilly has an amylin drug in Phase 2, and AstraZeneca and Metsera are developing similar agents.

名为CagriSema。礼来公司有一种处于第二阶段的艾米林药物，阿斯利康和Metsera公司也在开发类似的药物。

While the Gubra trial results so far suggest the drug is active, Agrawal added that it’s “hard to know whether it’s differentiated in any way.”

虽然Gubra的试验结果表明该药物是有效的，但Agrawal补充说，“很难知道它是否在任何方面有所不同。”

However, Gubra developed its drug to be more stable than other amylin-targeting drugs, Agrawal wrote. Those drugs commonly undergo a chemical reaction called “fibrillation” that

然而，Agrawal写道，Gubra开发的药物比其他针对艾米林的药物更稳定。那些药物通常会经历一种叫做“纤维化”的化学反应，导致稳定性问题。

can reduce potency

可能降低效力

, raise the risk of side effects and affect quality.

，增加副作用的风险并影响质量。